Camrelizumab

From WikiMD.org
Jump to navigation Jump to search

Camrelizumab

Camrelizumab (pronunciation: kam-re-liz-u-mab) is a humanized monoclonal antibody that is used in the treatment of various types of cancer. It is designed to bind to the programmed cell death protein 1 (PD-1) on the surface of certain immune cells, blocking a mechanism that helps cancer cells evade the immune system.

Etymology

The name "Camrelizumab" is derived from the combination of the words "cancer", "immune", and "antibody", reflecting its function as an immune checkpoint inhibitor that targets cancer cells. The suffix "-mab" is common in monoclonal antibodies.

Mechanism of Action

Camrelizumab works by binding to the PD-1 receptor on T cells, a type of white blood cell that is crucial for the body's immune response. By blocking this receptor, camrelizumab prevents cancer cells from using the PD-1 pathway to hide from the immune system, allowing the T cells to detect and attack the cancer cells.

Indications

Camrelizumab is used in the treatment of various types of cancer, including hepatocellular carcinoma (the most common type of liver cancer), nasopharyngeal carcinoma (a type of head and neck cancer), and esophageal squamous cell carcinoma. It is also being investigated for use in other types of cancer.

Side Effects

Common side effects of camrelizumab include fatigue, decreased appetite, rash, and diarrhea. More serious side effects can include immune-related adverse reactions, such as pneumonitis, hepatitis, colitis, and endocrinopathies.

Related Terms

External links

Esculaap.svg

This WikiMD article is a stub. You can help make it a full article.


Languages: - East Asian 中文, 日本, 한국어, South Asian हिन्दी, Urdu, বাংলা, తెలుగు, தமிழ், ಕನ್ನಡ,
Southeast Asian Indonesian, Vietnamese, Thai, မြန်မာဘာသာ, European español, Deutsch, français, русский, português do Brasil, Italian, polski